In these studies, the “G” allele of PNPLA3 has been implicated as a potential drug target for alcohol-related cirrhosis, Non-Alcoholic Fatty Liver Disease (NAFLD) and hepatic steatosis. Here, PNPLA3 is linked to fatty liver disease.